Results 81 to 90 of about 2,875 (114)

Donanemab Infusion and Recurrent Seizures in a Patient With Alzheimer's Disease and Epilepsy in the Absence of Amyloid-Related Imaging Abnormalities (ARIA). [PDF]

Cureus
Espinosa PS, Li S, Preisler J, Hennekens CH.   +3 more
europepmc   +1 more source

Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab. [PDF]

Neurocase
Schwartz NU, Dietz CD, Lin Z, Tammewar G, Bui N, La Joie R, Wang Y, Sreekrishnan A, Suhami D, VandeVrede L, Ljubenkov PA, Rojas JC.   +11 more
europepmc   +1 more source

Donanemab for early Alzheimer disease. [PDF]

Aust Prescr
europepmc   +1 more source

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. [PDF]

Alzheimers Dement
Raket LL, Lu M, Evans CD, Zimmer JA, Sparks J, Collins EC, Shcherbinin S, Wang H, Nery ESM, Epelbaum S, Dell'Agnello G, Brooks DA, Sims JR, Mintun MA.   +13 more
europepmc   +1 more source

A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes. [PDF]

Neurologist
Caselli RJ, Geldmacher DS, Schilling TB.
europepmc   +1 more source

The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population. [PDF]

J Prev Alzheimers Dis
Ijaz A, Mohyudin G.
europepmc   +1 more source

From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy. [PDF]

Lancet Reg Health Eur
Filippi M, Cecchetti G, Ghirelli A, Spinelli EG, Rugarli G, Pisano S, Samanes Gajate AM, Chiti A, Agosta F.   +8 more
europepmc   +1 more source

Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β-Directed Therapies and Other Labeling Updates. [PDF]

J Nucl Med
Koo H, Mattay V, Hofling AA, Wang SJ, Krainak D, Kim Y, Krudys K, Buracchio T, Marzella L.   +8 more
europepmc   +1 more source

Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community. [PDF]

Neurol Sci
Santos DH, da Silva AMP.
europepmc   +1 more source

Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis. [PDF]

Alzheimers Dement
Hoang MT, Kahn JG, Saha S, Trépel D.
europepmc   +1 more source